R Squared’s Nuvectis Pharma NVCT Stock Holding History

R Squared’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-310	Closed	-$1.68K	–	1089
2024 Q4	$1.68K	Buy	+310	New	+$1.94K	﹤0.01%	1478

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWM

Austin Wealth Management Austin, Texas $440M AUM 17.66% 1-Year Est. Return

R Squared's NVCT Position: Q1 2025 in Review

R Squared sold out of Nuvectis Pharma (NVCT) in Q1 2025, closing a stake of 310 shares — an estimated $1.68K sold.

R Squared first reported a position in NVCT in Q4 2024 and held it in 1 quarter. The position peaked at $1.68K in Q4 2024. 33 funds tracked by Wall St. Rank hold NVCT as of Q1 2025.

R Squared reported no remaining Nuvectis Pharma position as of Q1 2025 after selling out during the quarter.
R Squared sold 310 Nuvectis Pharma shares in Q1 2025, an estimated $1.68K.
R Squared first reported a position in Nuvectis Pharma in Q4 2024 and held it in 1 quarter.
R Squared's Nuvectis Pharma position peaked at $1.68K in Q4 2024.
33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.